A novel organoid model retaining the glioma microenvironment for personalized drug screening and therapeutic evaluation

A novel organoid model retaining the glioma microenvironment for personalized drug screening and therapeutic evaluation

Glioma is an aggressive brain tumor with a poor prognosis. Establishing an in vitro culture model that closely replicates the cellular composition and microenvironment of the original tumor has been challenging, limiting its clinical applications. Here, we present a novel approach to generate glioma...

Full description

Saved in:
Bibliographic Details
Main Authors: Chengjun Zheng, Peng Wang, Delong Zhang, Zheng Fang, Yutong Feng, Jie Chen, Jiahong Chen, Yiwen Fu, Bao Yang, Shuqing Yu, Li Min, Bo Xiao, Cencan Xing, Yang Yang, Jianfeng Wang, Donghua Zou, Shipeng Ning, Tong Liu, Jun Yan, Qian Zhao, Fei Sun, Qiaodong Chen, Ying Zhang, Tao Jiang, Lemin Zheng, Zhaoshi Bao
Format: Article
Language:English
Published: KeAi Communications Co., Ltd. 2025-11-01
Series:Bioactive Materials
Subjects:
Glioma
Organoid
Matrigel
Tumor microenvironment
Drug screening
Online Access:http://www.sciencedirect.com/science/article/pii/S2452199X25003081
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glioma is an aggressive brain tumor with a poor prognosis. Establishing an in vitro culture model that closely replicates the cellular composition and microenvironment of the original tumor has been challenging, limiting its clinical applications. Here, we present a novel approach to generate glioma organoids with a microenvironment (GlioME) from patient-derived glioma tissue. These organoids maintain the genetic and epigenetic characteristics of the primary tumor and preserve cell-to-cell interactions within the tumor microenvironment, including resident immune cells. Bulk RNA sequencing, whole exome sequencing, and DNA methylation analysis were used to confirm the molecular similarities between the organoids and primary glioma tissues. Immunofluorescence and flow cytometry were used to assess immune cell viability, comparing GlioME with floating glioma organoids. GlioME exhibited high responsiveness to chemotherapy and targeted therapy, demonstrating its potential for therapeutic screening applications. Notably, GlioME accurately predicted patient response to the recently approved MET inhibitor, vebreltinib. Thus, this organoid model provides a reliable in vitro platform for glioma microenvironment-related research and clinical drug screening.
ISSN:2452-199X

Similar Items